FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988045720> ?p ?o ?g. }

• W1988045720 endingPage "432" @default.
• W1988045720 startingPage "427" @default.
• W1988045720 abstract "Objectives To evaluate the activity and toxicity of AEZS-108 (Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors. Methods Women with epithelial ovarian, fallopian tube or primary peritoneal cancer, expressing LHRH receptors were eligible for this trial, when they had progression during treatment with a platinum based regimen or within 6 months after receiving a platinum based regimen and a previous taxane treatment. At least one measurable target lesion (RECIST) or CA-125 levels higher than twice the upper limit of normal range (GCIG-criteria) were required. Patients received AEZS-108 (267 mg/m2 equimolar to 76.8 mg/m2 of free doxorubicin) every 3 weeks as a two hour i.v. infusion. Results Fifty-five of 59 (93%) of ovarian cancer samples screened expressed LHRH receptors. 42 patients were enrolled in this study and received at least 1 infusion of AEZS-108 (ITT population). Of these 42 patients 6 (14.3%) had a partial response, 16 (38%) stable disease, 16 (38%) progressive disease and 4 patients were not evaluable. Median time to progression was 12 weeks (95% CI: 8–20 weeks), and median overall survival was 53 weeks (95% CI: 39–73 weeks). Toxicity profile was favorable. Conclusion AEZS-108 has a clinical activity in platinum refractory/resistant ovarian cancer which seems to be comparable to that of pegylated liposomal doxorubicin or to topotecan. Toxicity was comparably low. These data support the concept of a targeted chemotherapy for tumors expressing LHRH receptors." @default.
• W1988045720 created "2016-06-24" @default.
• W1988045720 creator A5002555374 @default.
• W1988045720 creator A5005795531 @default.
• W1988045720 creator A5020357121 @default.
• W1988045720 creator A5022527560 @default.
• W1988045720 creator A5025215479 @default.
• W1988045720 creator A5050467390 @default.
• W1988045720 creator A5050473616 @default.
• W1988045720 creator A5069635464 @default.
• W1988045720 creator A5078567055 @default.
• W1988045720 creator A5090376555 @default.
• W1988045720 date "2014-06-01" @default.
• W1988045720 modified "2023-10-16" @default.
• W1988045720 title "Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)" @default.
• W1988045720 cites W1960327677 @default.
• W1988045720 cites W1964736695 @default.
• W1988045720 cites W1968552800 @default.
• W1988045720 cites W1984458529 @default.
• W1988045720 cites W1984626255 @default.
• W1988045720 cites W2002710053 @default.
• W1988045720 cites W2007746075 @default.
• W1988045720 cites W2027689392 @default.
• W1988045720 cites W2082567167 @default.
• W1988045720 cites W2084688538 @default.
• W1988045720 cites W2088127009 @default.
• W1988045720 cites W2106516372 @default.
• W1988045720 cites W2118548073 @default.
• W1988045720 cites W2124058261 @default.
• W1988045720 cites W2139060364 @default.
• W1988045720 cites W2139248078 @default.
• W1988045720 cites W2148255405 @default.
• W1988045720 cites W4252372505 @default.
• W1988045720 doi "https://doi.org/10.1016/j.ygyno.2014.03.576" @default.
• W1988045720 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24713545" @default.
• W1988045720 hasPublicationYear "2014" @default.
• W1988045720 type Work @default.
• W1988045720 sameAs 1988045720 @default.
• W1988045720 citedByCount "36" @default.
• W1988045720 countsByYear W19880457202014 @default.
• W1988045720 countsByYear W19880457202016 @default.
• W1988045720 countsByYear W19880457202017 @default.
• W1988045720 countsByYear W19880457202018 @default.
• W1988045720 countsByYear W19880457202019 @default.
• W1988045720 countsByYear W19880457202020 @default.
• W1988045720 countsByYear W19880457202021 @default.
• W1988045720 countsByYear W19880457202022 @default.
• W1988045720 countsByYear W19880457202023 @default.
• W1988045720 crossrefType "journal-article" @default.
• W1988045720 hasAuthorship W1988045720A5002555374 @default.
• W1988045720 hasAuthorship W1988045720A5005795531 @default.
• W1988045720 hasAuthorship W1988045720A5020357121 @default.
• W1988045720 hasAuthorship W1988045720A5022527560 @default.
• W1988045720 hasAuthorship W1988045720A5025215479 @default.
• W1988045720 hasAuthorship W1988045720A5050467390 @default.
• W1988045720 hasAuthorship W1988045720A5050473616 @default.
• W1988045720 hasAuthorship W1988045720A5069635464 @default.
• W1988045720 hasAuthorship W1988045720A5078567055 @default.
• W1988045720 hasAuthorship W1988045720A5090376555 @default.
• W1988045720 hasConcept C121608353 @default.
• W1988045720 hasConcept C126322002 @default.
• W1988045720 hasConcept C134018914 @default.
• W1988045720 hasConcept C143998085 @default.
• W1988045720 hasConcept C2776694085 @default.
• W1988045720 hasConcept C2777511904 @default.
• W1988045720 hasConcept C2780427987 @default.
• W1988045720 hasConcept C2781303535 @default.
• W1988045720 hasConcept C2781413609 @default.
• W1988045720 hasConcept C530470458 @default.
• W1988045720 hasConcept C71924100 @default.
• W1988045720 hasConcept C90924648 @default.
• W1988045720 hasConcept C98274493 @default.
• W1988045720 hasConceptScore W1988045720C121608353 @default.
• W1988045720 hasConceptScore W1988045720C126322002 @default.
• W1988045720 hasConceptScore W1988045720C134018914 @default.
• W1988045720 hasConceptScore W1988045720C143998085 @default.
• W1988045720 hasConceptScore W1988045720C2776694085 @default.
• W1988045720 hasConceptScore W1988045720C2777511904 @default.
• W1988045720 hasConceptScore W1988045720C2780427987 @default.
• W1988045720 hasConceptScore W1988045720C2781303535 @default.
• W1988045720 hasConceptScore W1988045720C2781413609 @default.
• W1988045720 hasConceptScore W1988045720C530470458 @default.
• W1988045720 hasConceptScore W1988045720C71924100 @default.
• W1988045720 hasConceptScore W1988045720C90924648 @default.
• W1988045720 hasConceptScore W1988045720C98274493 @default.
• W1988045720 hasIssue "3" @default.
• W1988045720 hasLocation W19880457201 @default.
• W1988045720 hasLocation W19880457202 @default.
• W1988045720 hasOpenAccess W1988045720 @default.
• W1988045720 hasPrimaryLocation W19880457201 @default.
• W1988045720 hasRelatedWork W1995085344 @default.
• W1988045720 hasRelatedWork W2085844047 @default.
• W1988045720 hasRelatedWork W2146898191 @default.
• W1988045720 hasRelatedWork W2352364737 @default.
• W1988045720 hasRelatedWork W2373226427 @default.
• W1988045720 hasRelatedWork W2387456186 @default.
• W1988045720 hasRelatedWork W2388730008 @default.
• W1988045720 hasRelatedWork W4200616568 @default.

• next